AZN vs LLY
AstraZeneca PLC and Lilly (Eli), both Healthcare
Lilly (Eli) is the larger company at $980B against $271B. On trailing earnings AZN is the cheaper of the two at a P/E of 27.4 against 39.9, a gap that is only a bargain if the two are growing at similar rates. Over the past year LLY returned +61% against +13% for AZN.
| Figure | AZN | LLY |
|---|---|---|
| Last close | $166 | $1190 |
| Market cap | $271B | $980B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.4 | 39.9 |
| Dividend yield | n/a | 0.5% |
| 1-year return | +13% | +61% |
| 5-year return | +61% | +412% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Lilly (Eli)
Revenue of $23B in Q2 2026, net income $7.1B. Its largest reported line is Cardiometabolic Health, 47% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.